glp 1 new indications The science on GLP-1 receptor agonists has outpaced the public narrative. While headlines chase the latest prescription numbers, evidence-based practice demands we hold the line: obesity is a chronic, relapsing condition; not Beyond Injections: How Oral GLP-1s

Description

But because the landscape around compounded GLP-1 medications has shifted dramatically since the FDA resolved the semaglutide shortage in February 2025, and what was once a straightforward decision now involves regulatory gray areas, legal battles, and quality control questions that most people never expected to navigate

100% Pass-Through PBMs: Working with a modern, 100% pass-through PBM (like SmithRx) ensures you can understand the actual cost of medications

Accessed 22/2/2025 Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB

Expect follow-up appointments at intervals such as: 2-4 weeks: Initial check-in for tolerance and early response 6-8 weeks: Assessment of initial results and protocol adjustments 12 weeks: Comprehensive evaluation with repeat lab work Ongoing: Quarterly or semi-annual monitoring depending on protocol Understanding typical peptide results timelines helps calibrate expectations

Monitor and Evaluate : Regularly assess how the medication is impacting both your weight and pelvic floor symptoms, and adjust treatment plans as needed